To date, research and development (R&D) within the pharmaceutical industry has been dominated by a developed-market perspective. But as emerging markets change Pharma’s worldview, it’s time for drugmakers to fundamentally rethink how R&D is done.
Healthy margins and little appetite for risk have kept most pharmaceutical companies close to home, for all but their manufacturing activities. But as financial pressures increase, pharmaceutical executives are finding that going offshore is not only less risky than it once was but also too attractive to ignore.
© 2004-2013 Ochre Media. All rights reserved. 
